Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. The company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Follow-Up Questions
Who is the CEO of Intensity Therapeutics Inc?
Mr. Lewis Bender is the Chairman of the Board of Intensity Therapeutics Inc, joining the firm since 2012.
What is the price performance of INTS stock?
The current price of INTS is $0.2755, it has increased 5.59% in the last trading day.
What are the primary business themes or industries for Intensity Therapeutics Inc?
Intensity Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Intensity Therapeutics Inc market cap?
Intensity Therapeutics Inc's current market cap is $13.5M
Is Intensity Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Intensity Therapeutics Inc, including 2 strong buy, 7 buy, 2 hold, 0 sell, and 2 strong sell
